MyFinsight
Home
Blog
About
Net proceeds from
issuance of common stock
$1,294K
(6.24%↑ Y/Y)
Net proceeds from
exercise of stock options...
$560K
(-22.65%↓ Y/Y)
Net cash flows from
financing activities
$1,597K
(-87.66%↓ Y/Y)
Canceled cashflow
$257K
Net decrease in cash
and cash...
-$842K
(37.58%↑ Y/Y)
Canceled cashflow
$1,597K
Change in fair value of
derivative liabilities
$3,156K
(181.53%↑ Y/Y)
Accrued interest on
convertible debt - related...
$1,847K
(-35.76%↓ Y/Y)
Stock-based compensation
expense
$963K
(-0.52%↓ Y/Y)
Accounts payable,
accrued expenses and...
$472K
(114.57%↑ Y/Y)
Non-cash interest
expense
$158K
(-77.30%↓ Y/Y)
Prepaid expenses and
other assets
-$74K
(82.71%↑ Y/Y)
Amortization of right to use
lease asset
$4K
(-66.67%↓ Y/Y)
Net proceeds from
convertible line of credit ...
-$257K
(-102.34%↓ Y/Y)
Net cash from
operating activities
-$2,439K
(82.93%↑ Y/Y)
Canceled cashflow
$6,674K
Net loss
-$9,113K
(46.87%↑ Y/Y)
Back
Back
Cash Flow
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)
source: myfinsight.com